BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37062034)

  • 1. Switchable CAR T cell strategy against osteosarcoma.
    Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
    Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
    Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
    Front Immunol; 2021; 12():691741. PubMed ID: 34211478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
    Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
    Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
    Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
    BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
    Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
    Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
    EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
    Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
    Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
    Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
    J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
    Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
    Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
    Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
    Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
    Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing T-cell sources determines CAR-T cell activity in neuroblastoma.
    García-García L; G Sánchez E; Ivanova M; Pastora K; Alcántara-Sánchez C; García-Martínez J; Martín-Antonio B; Ramírez M; González-Murillo Á
    Front Immunol; 2024; 15():1375833. PubMed ID: 38601159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirecting gene-modified T cells toward various cancer types using tagged antibodies.
    Tamada K; Geng D; Sakoda Y; Bansal N; Srivastava R; Li Z; Davila E
    Clin Cancer Res; 2012 Dec; 18(23):6436-45. PubMed ID: 23032741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
    Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
    Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.